MSD initiates construction on $3bn Virginia drug manufacturing site
Merck & Co (MSD) has broken ground on its new pharmaceutical manufacturing Centre of Excellence in Virginia, US, amid looming …
Post
-
-
Lundbeck and Contera partner for oligonucleotide-based medicines
H Lundbeck and Contera Pharma have announced a research partnership aimed at expediting the discovery as well as development of …
-
From Creams to Biologics: Adapting Dermatology Trials to New Therapies
GlobalData estimates suggest that, across seven of the world’s major pharmaceutical markets - the US, the big five in Europe …
-
Biotech to boardroom: How early oncology data builds investor confidence
Developing oncology medications is a complicated and costly process. While clinical trial designs have improved, these trials still face difficulties …
-
FDA approves Roche’s Gazyva for lupus nephritis
The US Food and Drug Administration (FDA) has granted approval for Roche's Gazyva/ Gazyvaro (obinutuzumab) to treat adult patients with …
-
Biotech to boardroom: How early oncology data builds investor confidence
Developing oncology medications is a complicated and costly process. While clinical trial designs have improved, these trials still face difficulties …
-
FDA approves Roche’s Gazyva for lupus nephritis
The US Food and Drug Administration (FDA) has granted approval for Roche's Gazyva/ Gazyvaro (obinutuzumab) to treat adult patients with …
-
FDA approves Glaukos’ Epioxa as incision-free corneal disease treatment
The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal disease …
-
ESMO 2025: J&J eyes Rybrevant indication expansion to HNSCC on Phase II victory
Johnson & Johnson’s (J&J’s) bispecific Rybrevant (amivantamab) could provide an effective, novel option for patients with head and neck squamous …
-
Infertility treatment amongst first drugs included on FDA’s new priority voucher scheme
The US Food and Drug Administration (FDA) has selected the first products to be included on the Commissioner’s National Priority …
-
FDA greenlight for Roche’s Alzheimer’s disease test sparks care paradigm shift
The US Food and Drug Administration’s (FDA) recent clearance of Roche’s blood-based Alzheimer’s disease test will boost therapeutic intervention options …
-
ESMO 2025: Eli Lilly’s Verzenio extends survival in high-risk early breast cancer
Eli Lilly’s Verzenio (abemaciclib) boosted overall survival (OS) in the adjuvant breast cancer setting during a late-stage trial. In the Phase …
-
ESMO 2025: Novartis’s Pluvicto delays progression to end-stage for mHSPC
At the European Society of Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from 17 to 21 October, results …
-
ESMO 2025: Padcev/Keytruda combo has potential as new SOC for perioperative bladder cancer
Results from the Phase III registrational EV-303/KEYNOTE-905 study evaluating the combination of Pfizer’s and Astellas’ nectin-4 targeting antibody-drug conjugate Padcev …
-
ESMO25: Keytruda combo defies doubt, delivers PFS and OS gains in ovarian cancer
Platinum-resistant ovarian cancer (PROC) remains one of the most treatment-refractory malignancies, with a median overall survival (OS) of less than …
